Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurtotecan Liposome in Advanced/Recurrent Ovarian Cancer
NCT00010179Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Oct 2000
- Primary completion
- Oct 2002
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 2
01
Overview
A Phase 2 trial of lurtotecan liposome in ovarian epithelial cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Canadian Cancer Trials Group. Started Oct 2000; status: completed.
02
Drugs
lurtotecan liposome
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00010179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00010179.